A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of a Nerve Support Formula on Neuropathic Pain in Individuals Suffering from Type II Diabetes Mellitus
William Cross,Shalini Srivastava
DOI: https://doi.org/10.2147/JPR.S397777
IF: 2.8319
2023-03-31
Journal of Pain Research
Abstract:William Cross, 1 Shalini Srivastava 2 1 Research and Development, Vasocorp, Hiram, GA, USA; 2 Clinical Development, Vedic Lifesciences, Thane, India Correspondence: Dr Shalini Srivastava, 118, Morya House, Opp. Infinity Mall, Andheri (West), Mumbai, 400053, Maharashtra, India, Email Background: The primary objective of the present study was to evaluate the effects of a Nerve Support Formula NeuropAWAY ® on diabetic neuropathic pain. Methods: This double-blind, placebo-controlled, randomized trial was conducted between August 2020 and February 2021. Patients aged ≥ 40 and ≤ 65 years with a history of type 2 diabetes (T2D) with a confirmed diagnosis of diabetic neuropathic pain were included in the study. The primary efficacy endpoint was to assess the effect of the 42 days administration of the Nerve Support Formula on the neuropathic pain as assessed by the 11 point Pain Intensity Numeric Rating Scale (PI-NRS). The secondary objectives were to assess the effect on plasma vitamin B12 levels, nerve conduction velocity, blood flow velocity, Brief Pain Inventory, Neuropathy Total Symptom Score, and Insomnia Severity Index. Results: The enrolled study population (n=59) was randomized in two study groups; the Investigational Product (IP) group - Nerve Support Formula (n=27) and placebo group (n=32). The mean age of these participants was 52.63 and 53.72 for IP and placebo group, respectively. The mean (SD) HbA1c levels for IP and placebo group were 8.37 (0.85) and 8.16 (0.86), respectively. By the end of the study (Day 42) the decrease in PI-NRS scores for the IP group was maximal (↓ 61.32%) and highly significant ( p < 0.001) in comparison to the placebo group (↑ 2.47%). Significant improvements ( p < 0.05) were also noted in the secondary efficacy variables after 42 days of IP intake. Conclusion: The formula was found to be significantly effective as compared to placebo in reducing pain and other sensory symptoms related to the diabetic peripheral neuropathy. Keywords: diabetes mellitus, neuropathic pain, supplements, vitamin B12, placebo controlled Diabetes Mellitus is a rising healthcare condition that now affects over 451 million people worldwide, 1 with the number predicted to rise to 693 million by 2045. 2 Diabetic peripheral neuropathy (dPN) is the most frequent of the typical medical consequences, and it is associated with increased morbidity and death. It is defined as a unique type of neurodegeneration that occurs in the peripheral nervous system, which impairs nerve function by targeting the sensory, autonomic, and motor axons. 3–5 Over time, at least 50% of people with T2D will acquire dPN at some point in their lives. 6 It is a result of nerve damage and is produced by a combination of metabolic, autoimmune, neurovascular, lifestyle, mechanical nerve injury, hereditary characteristics, and other factors. Furthermore, dPN is the major cause of disability in people with T2D, owing to its consequences, which include autonomic abnormalities and diabetic foot events. Painful diabetic neuropathy not only deteriorates quality of life, affects sleep and recreation, disrupts mental well-being, causes melancholy, ataxia, and anxiety, but it's also linked to noncompliance with treatment. 7 According to the findings, neuropathic pain has a higher psychological cost than nociceptive pain and is also regarded to be more severe than other forms of pain. Significant pain alleviation has been shown to significantly enhance quality-of-life indicators, such as sleep patterns and overall well-being. Known analgesic medications, such as non-steroidal anti-inflammatory medicines (NSAIDs) and opiates, 8–10 are commonly used to treat neuropathic pain associated with dPN. As reported in a meta-analyses, 11 most of the pharmacological treatments have limited efficacy with an effect size as small as <0.5. This concern drew the attention of the medical fraternity towards nutraceuticals and other nonpharmaceutical supplements that may serve to work in synergy with existing pharmaceutical-based treatment regimens for combatting chronic neuropathic pain. The antioxidant, anti-inflammatory, anti-apoptotic, neuroprotective, and calcium inhibitory activities of supplemental vitamins and amino acids have demonstrated significant analgesic effects. 12 People withstanding long-term diabetes mellitus often present with vitamin B12 deficiency, thereby triggering peripheral neuropathy. 13 Methylcobalamin (MeCbl) is known to have a neuroprotective role by aiding in the synthesis of neuronal lipids as well as regeneration of axonal nerves. 14,15 A study has reported a decrease in the -Abstract Truncated-
clinical neurology